Activation of the kinase RAF and its downstream targets leads to cardiomyocyte hypertrophy. It has been hypothesized that B-RAF might be the main activator of MEK in various cell types. Therefore, the aim of this study was to investigate the role of B-RAF and its modulating factors in cardiomyocyte hypertrophy.
Introduction
Cardiomyocytes respond to stress and other growth stimuli by an increased rate of protein synthesis resulting in increased cell volume 1 and ultimately thickening of the heart. Human cardiac hypertrophy may compensate for increased demand, but may also represent a detrimental response associated with the development of heart failure. 2 Neurohormones and mechanical stimuli cause cardiomyocyte hypertrophy 3 -5 which is often mediated via G-protein-coupled receptors. 6 The guanine nucleotide binding protein RAS is activated by many prohypertrophic stimuli and its activation has been associated with cardiac hypertrophy. 7, 8 Injection of activated RAS in neonatal rat cardiomyocytes (NRCs) promotes changes in gene expression and cell structure characteristic of cardiomyocyte hypertrophy. 9 Transgenic overexpression of RAS results in cardiac hypertrophy and heart failure in mice. 10 Activated GTP-bond RAS recruits the RAF serine/threonine kinase to the plasma membrane where it is activated 11 -13 starting the mitogen-activated protein kinase (MAPK) cascade that includes the MAPK/ERK kinase (MEK) 1/2 and its downstream targets the extracellular signal-regulated kinases (ERK) 1/2. 14 -16 The role of the RAF/MEK signalling pathway in the pathogenesis of cardiac hypertrophy has been discussed controversially. In cultured cardiomyocytes, the activation of the RAF/MEK pathway has been reported to be essential for the development of hypertrophy, 17 on the other hand ERK activation seems to be required for the anti-hypertrophic effect of atrial natriuretic factor (ANF). 18 Furthermore, the RAF/MEK pathway regulates hypertrophic gene induction, but may not be sufficient for cellular morphological changes associated with cardiomyocyte hypertrophy. 19, 20 Cardiacspecific expression of activated MEK in mice results in robust concentric hypertrophy. 21 Previous studies by Harris et al. demonstrated that C-RAF kinase activity was essential for cardiac hypertrophy in transgenic mice. 22 In humans, there are three functional RAF proteins-A-RAF, B-RAF, and C-RAF-which differ in their regulatory mechanism. 23 B-RAF is able to bind and activate C-RAF in a RAS-dependent manner that appears to require transphosphorylation of C-RAF by B-RAF. 24 -26 Although all RAF isoforms can bind and activate MEK1/2 in vitro, B-RAF binds and phosphorylates MEK1/2 more efficiently than A-RAF or C-RAF. 27, 28 Cell-fraction studies led to the suggestion that B-RAF is the most important MEK kinase either directly or through its ability to recruit and activate C-RAF. 29, 30 However, the role of B-RAF as main MEK kinase and its modulation through various proteins is still unclear in cardiomyocyte hypertrophy. To determine the role of B-RAF activation, we analysed the hypertrophic potential of NRCs and MEK kinase activity with and without B-RAF inhibition. In order to identify new modulators of B-RAF activity, a eukaryotic expression screen for cDNAs encoding potential modulators of B-RAF/MEK interaction was performed. Reticulocalbin 1 (RCN1), a potential negative regulator of B-RAF activation, was further characterized for its ability to modulate cardiomyocyte hypertrophy.
Methods

Constructs for expression screen and cDNA library
The Mammalian Two-Hybrid System (Promega) was used to clone a pair of bait and prey expression vectors where MEK1 was fused to the DNA-binding domain of GAL4 (GAL4-MEK1) and B-RAF to the VP16 transcription activation domain (VP16-BRAF). A full-length whole-genome mouse embryo cDNA library was purchased from Life Technologies and cDNA pools were prepared using the Perfectprep Plasmid 96 Vac Kit (5 PRIME).
Transient transfection and luciferase-reporter assay
A total of 5 × 10 4 COS-7 cells per well were cultured in a 24-well plate in DMEM with 10% FBS. Cells were transfected with 50 ng of firefly luciferase-reporter pG5luc together with 50 ng of each expression plasmid encoding fusion proteins GAL4-MEK1 and VP16-BRAF with additional 250 ng of cDNA expression library by using 1.2 mL FuGENE 6 reagent (Roche Molecular Biochemicals). Transfection efficiency was normalized to renilla reniformis luciferase expression. Twenty-four hours post transfection, cells were harvested in 100 mL passive lysis buffer (Promega) and 20 mL of cell lysate was used for dual-luciferase assay (Promega). For the initial screen, cDNA pools containing 100 single cDNA clones were used. For selection, positive pools of cDNA expression library were retransformed in Escherichia coli DH5a competent cells. Ninetysix single colonies were picked for each positive pool. Plasmid isolation was performed as described above and 12 single cDNA expression clones were combined as sub-pools. Plasmids were purified from positive sub-pools and used to transfected COS-7 cells as described above. Plasmid DNA from single colonies was prepared and sequenced.
2.3 Cloning of recombinant adenovirus encoding for RCN1 and for synthetic microRNAs (miRNAs) targeting rat RCN1
Full-length RCN1 from pcDNA TM DEST40 Vector (Life Technologies) of cDNA expression library was transferred to a small shuttle plasmid (Microbix) using the Gateway w cloning technology (Life Technologies) according to manufacturer's instructions. After recombination in HEK293 cells, adenovirus was purified by cesium chloride gradient. For RNA interference (RNAi)-mediated knockdown, two oligonucleotides encoding synthetic miRNAs specifically targeting rat Rcn1 mRNA were designed in silico using the BlockiT RNAi designer algorithm (Life Technologies) and cloned into the pcDNA TM 6.2GW plasmid : miR1 TGCTGTAACAAGGCCGTCTCCA TCACGTTTTGGCCACTGACTGACGTGATGGACGGCCTTGTTA, miR2 TGCTGTTCTGTACCCGTTTGATCCAAGTTTTGGCCACTGACTGA CTTGGATCACGGGTACAGAA. As negative control, we used a miR described previously: control-miR GAAATGTACTGCGCGTGGAGACG TTTTGGCCACTGACTGACGTCTCCACGCAGTACATTT.
31 miR1 and miR2 are predicted to target only RCN1, control-miR is predicted not to target any known mammalian gene. Adenoviruses encoding for synthetic miRNAs were generated using Admax vectors (Microbix).
Isolation and culture of neonatal rat ventricular cardiomyocytes (NRCs)
One-to two-day-old Wistar rats were decapitated and hearts were excised. After mincing in phosphate-buffered saline (PBS) buffer containing 0.2% (w/v) trypsin (BiochromAG) and 0.1% (w/v) collagenase type II (Worthington), four digestion cycles were carried out to dissociate the cells. Cells were centrifuged, resuspended in DMEM:F12 medium with 10% (v/v) foetal calf serum (Firma) and preplated on tissue culture dishes to remove contaminating fibroblasts. Cardiomyocytes were finally plated on gelatine-coated tissue culture dishes.
Adenoviral gene transfer
Adenovirus was generated by ligation of cDNA-sequence encoding RCN1, RCN1-miRNA, control-miRNA, constitutively active C-RAF-BXB (kindly provided by Slupsky and Weber) 26 or b-galactosidase as control into a shuttle-vector (Microbix) and by FLP recombination with pBGHfrtDE1,3FLP (Microbix) in HEK293 cells. Sixteen hours after isolation, cells in serum-free medium were infected with adenoviruses. For additional experiments, 5 mM PE, 5 mM SB590885, or vehicle as control were applied for the time indicated.
Immunofluorescence experiments and planimetric measurement
To analyse hypertrophic growth of NRCs, the cells were fixed using methanol:acetone (7:3) and permeabilized with 0.1% (v/v) Triton X-100 in PBS.
Monoclonal antibody against sarcomeric a-actinin (Sigma-Aldrich) was used at a dilution of 1:200. A Cy3-coupled anti-mouse secondary antibody (Dianova) was used at 1:600 for 1 h. The nuclei were labelled by DAPI and cell surface area of NRCs was determined applying AxioVision (Carl Zeiss Vision) and ImageJ. All cell surface area measurements were carried out in a blinded manner containing at least 3 biological replicates with more than 80 cells per condition.
Immunoblot analysis
Cell lysates or immunoprecipitates were subjected to SDS -PAGE and transferred to a nitrocellulose 18 membrane (Whatman). Application of primary antibodies anti-GAPDH (BioTrend), anti-phospho-MEK1/2 and MEK1/2 (Cell Signaling Technology), anti-phospho JNK (Santa Cruz) and JNK (Cell Signaling Technology), anti-RCN1 (Bethyl Laboratories) was followed by incubation with a horseradish peroxidase coupled secondary antibody (GE Healthcare). Visualization was achieved using a chemiluminescence kit (GE Healthcare). Alphaview software (Alpha Innotech) was used for image acquisition and densitometry. The RAS Activation Assay Kit (Millipore) was used according to manufacturer's protocol to investigate the presence of activated RAS.
RNA isolation and real-time PCR
Transverse aortic constriction (TAC) was carried out as described previously. 32 Briefly, mice were anaesthetized with injections of ketamine and xylazine (ip: 100 mg/kg + 5 mg/kg). Mice were killed in isofluran anaesthesia (5%) by cervical dislocation. Animal experiments were conducted according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the Animal Ethics Committee of the University of Gö ttingen and the German federal state government. Mouse tissue for RNA and protein extraction was kindly provided by K. Toischer. 33 Total RNA was extracted using RNeasy Fibrous Tissue Mini Kit (Qiagen) or QIAshredder (Qiagen) for NRCs. Quantitative real-time PCR was performed using IQ SYBR Green Supermix (Bio-Rad Laboratories). Starting quantities were extrapolated from standard curves for each primer set and normalized to 18S and calsequestrin RNA levels.
Statistical analysis
Statistical analyses were carried out using Prism software version 5.01 (GraphPad). All data were reported as mean value + SEM. Differences between control cells and treated cells were analysed by Mann-Whitney U tests for non-parametric data and by independent t tests for parametric data. For experiments using three or more conditions, data were analysed using ANOVA plus Bonferroni post-test. Statistical significance was defined as P , 0.05.
Results
B-RAF inhibition impedes cardiomyocyte hypertrophy
To test whether B-RAF activity plays a crucial role in the development of cardiomyocyte hypertrophy, we pre-treated NRCs with vehicle or the pharmacological B-RAF inhibitor SB590885 and then stimulated hypertrophic growth with the agonist phenylephrine (PE). After incubation with the inhibitor SB590885, we observed a decrease in cell surface area with and even without PE treatment. Compared with a vehicletreated group, the inhibition of B-RAF activity led to a significant reduction in relative cardiomyocyte cell surface area (1.00 + 0.03, n ¼ 3, vs. 0.76 + 0.02, n ¼ 3, P , 0.0001). While stimulation with PE led to a robust increase in cardiomyocyte cell surface area in vehicle-treated cells (1.23 + 0.02, n ¼ 3), pre-treatment with B-RAF inhibitor SB590885 completely impeded cardiomyocyte hypertrophy induced by PE (0.74 + 0.02, n ¼ 3, P , 0.0001) ( Figure 1A and B). Because cellular hypertrophy is typically accompanied by increased expression of ANF and brain natriuretic peptide (BNP)-mRNA, we analysed expression of these genes in NRCs. Stimulation of NRCs with PE led to a robust increase of ANF-mRNA (1.98 + 0.12) and BNP-mRNA (1.84 + 0.16) expression compared with unstimulated controls (ANF: 1.00 + 0.03, n ¼ 4, P , 0.0001; BNP: 1.00 + 0.10, n ¼ 4, P , 0.005). Compared with vehicle-treated control, the inhibition of B-RAF activity led to a significant reduction in ANF-(0.87 + 0.16, n ¼ 4, P , 0.0001) and BNP-mRNA expression (0.95 + 0.21, n ¼ 4, P , 0.0005) after PE stimulation ( Figure 1C and D) .
The absence of hypertrophic growth of NRCs after B-RAF inhibition can be explained by reduced MEK1/2 phosphorylation. NRCs were pretreated with the B-RAF inhibitor SB590885 or vehicle and stimulated with PE. Basal phosphorylation of MEK1/2 was significantly reduced in NRCs with inhibited B-RAF activation (0.16 + 0.01, n ¼ 3) compared with vehicle-treated controls (1.13 + 0.05, n ¼ 3, P , 0.05). Likewise, after hypertrophic stimulation with PE, MEK1/2 phosphorylation was significantly reduced in NRCs with inhibited B-RAF activation (1.01 + 0.06, n ¼ 3) compared with controls (2.64 + 0.15, n ¼ 3, P , 0.001) ( Figure 1E ).
RCN1 is a new negative modulator of B-RAF activity
Given the marked impact of B-RAF/MEK1, we sought to identify new signalling modulators that control activation of B-RAF towards MEK1 using an unbiased cDNA expression screen coupled to dual-luciferase reporter assay reporting B-RAF-MEK1 interaction (Figure 2A) . To verify the B-RAF reporter assay, we analysed known inhibitors and activators of the B-RAF/MEK1 interaction. As negative controls, each of the fusion proteins was measured for luciferase activity in the presence of GAL4 or VP16 alone, which did not induce luciferase expression (VP16-BRAF: 0.006 + 0.001, n ¼ 4; GAL4-MEK1: 0.013 + 0.003, n ¼ 4). Basal activity of B-RAF led to interaction of both fusion proteins alone (VP16-BRAF, GAL4-MEK1) resulting in a robust luciferase expression (0.969 + 0.059, n ¼ 4). The E3 ubiquitin ligase IMP (impedes mitogenic signal propagation), a known inhibitor of the MAPK signalling cascade, significantly reduced luciferase expression (0.441 + 0.026) compared with basal activity (n ¼ 4, P , 0.001). In contrast, a constitutive active H-RasV12 mutant led to a significantly increased B-Raf kinase activity (1.523 + 0.028) in comparison with basal activity (n ¼ 4, P , 0.0001) ( Figure 2B) .
For the cDNA library screen, we investigated 1000 cDNA pools representing at least 100 000 individual cDNA clones. We measured changes in B-Raf kinase activity after transfection of expression plasmids encoding these fusion proteins together with pools of 100 cDNA clones. Individual clones were isolated from positive pools using sub-selection. These analyses identified RCN1 as new negative modulator of basal B-RAF kinase activity. Compared with control, enhanced expression of RCN1 evoked a significant reduction in the activity of B-RAF (0.969 + 0.059, n ¼ 4 vs. 0.397 + 0.128, n ¼ 4; P , 0.0001) ( Figure 2B ).
Rcn1 expression is up-regulated in cardiac hypertrophy and failure
To assess whether RCN1 was differentially expressed in cardiac hypertrophy, we examined RCN1-protein and mRNA expression in the hearts of wild-type mice subjected to TAC. Western blot analyses revealed a significant increase in RCN1 protein expression in TAC-operated mice (1.38 + 0.20, n ¼ 6) compared with sham-operated controls (0.63 + 0.14, n ¼ 6, P , 0.05) ( Figure 3A and B) . Compared with sham-operated controls (1.00 + 0.06, n ¼ 6) the m-RNA expression of Rcn1 was significantly up-regulated in TAC mice (1.51 + 0.12, n ¼ 6, P , 0.0005) ( Figure 3C ).
Adenoviral overexpression of RCN1 impedes cardiomyocyte hypertrophy
To further elucidate the role of RCN1 in cardiomyocyte hypertrophy, we utilized adenoviral gene transfer for overexpression of RCN1 (Ad-RCN1) in NRCs. Infection of NRCs led to a dose-dependent overexpression of RCN1 on protein level. In NRCs, the expression of RCN1 led to a significantly reduced MEK1/2 phosphorylation in a dosedependent manner (pMEK/tMEK: 1.85 + 0.09 MOI 0, 1.64 + 0.08 MOI 1, 1.56 + 0.02 MOI 5, 1.13 + 0.07 MOI 10, n ¼ 3, P , 0.0001), while phosphorylation of c-Jun N-terminal kinase (JNK) was not significantly altered ( Figure 4A ). NRCs were infected with Ad-RCN1 or a b-galactosidase overexpressing adenovirus as control (Ad-bGAL) and treated with vehicle or PE. Compared with the vehicle control, stimulation with PE led to a robust increase in cardiomyocyte cell surface area (1.00 + 0.015, n ¼ 3 vs. 1.31 + 0.02, n ¼ 3, P , 0.0001). RCN1 overexpression completely abrogated cardiomyocyte hypertrophy induced by PE (0.76 + 0.01, n ¼ 3, P , 0.0001 vs. PE) ( Figure 4B and C ) . Stimulation of NRCs with PE led to a robust increase of ANF-mRNA (1.71 + 0.20, n ¼ 4) and BNP-mRNA (1.54 + 0.12, n ¼ 4) expression compared with unstimulated controls (ANF: 1.00 + 0.07, n ¼ 4, P , 0.005; BNP: 1.00 + 0.16, n ¼ 4, P , 0.05). Compared with vehicle-treated controls, the overexpression of RCN1 led to a significant reduction in ANF-mRNA (0.12 + 0.09, n ¼ 4, P , 0.05) and BNP-mRNA expression (1.05 + 0.06, n ¼ 4, P , 0.05) after PE stimulation ( Figure 4D and E).
RCN1 deficiency leads to hypertrophic growth of cardiomyocytes
Having established that enhanced expression of RCN1 impedes hypertrophic growth in cardiomyocytes, we evaluated whether downregulation of RCN1 might facilitate the development of cardiomyocyte hypertrophy. For this purpose, we generated two different adenovirus expressing synthetic miRNAs targeting RCN1. The most potent were chosen for further analysis (Ad-miR1, Ad-miR2). The treatment of NRCs with Ad-miR1 (MOI 25) led to a 62% reduction and treatment with Ad-miR2 (MOI 25) to a 73% reduction in RCN1 expression. This was accompanied by a significant increase in MEK1/2 phosphorylation in NRCs with reduced RCN1 expression (Ad-miR1: 3.16 + 0.59, n ¼ 3; Ad-miR2: 4.02 + 0.16, n ¼ 3) compared with controls (2.25 + 0.15, n ¼ 3, P , 0.05) ( Figure 5A ). The knockdown of RCN1 in NRCs through miR1 and miR2 resulted in a significant increase in cardiomyocyte cell surface area (Ad-miR1: 1.19 + 0.03, n ¼ 3; Ad-miR2: 1.38 + 0.03, n ¼ 3) compared with NRCs infected with control-miR (Ad-con-miR 0.98 + 0.02, n ¼ 3, P , 0.0001) ( Figure 5B), suggesting that RCN1 was not only sufficient, but also required for the inhibition of cardiomyocyte hypertrophy. Overexpression of Ad-miR2 in NRCs also led to a significant increase of ANP (1.54 + 0.20, n ¼ 4) and BNPexpression (1.62 + 0.08, n ¼ 4) compared with control (ANP: 1.00 + 0.15, BNP: 1.00 + 0.05, n ¼ 4, P , 0.005) ( Figure 5C and D) .
To verify the initial results obtained by the B-RAF reporter assay in COS cells in NRCs, adenoviruses encoding fusion proteins VP16-B-RAF (AdVP16-BRAF), GAL4-MEK1 (AdGAL4-MEK1), and the firefly luciferase reporter (Ad-luc) were generated. NRCs were transduced with these constructs and additional adenoviruses (Ad-RCN1, Ad-IMP, Ad-miR1, and Ad-miR2) (MOI 25). Consistent with the data from COS cells, the basal activity of B-RAF led to a robust luciferase expression after transduction with reporter constructs (2.10 + 0.05, n ¼ 3). Additional overexpression of the RAF/MEK inhibitor IMP led to a significantly reduced B-RAF activation (1.22 + 0.06, n ¼ 3, P , 0.0001) in comparison with basal activity. Overexpression of RCN1 significantly reduced B-RAF activation (1.00 + 0.04, n ¼ 3, P , 0.0001) while knockdown of RCN1 by miR2 significantly increased the B-RAF activity (miR1: 2.24 + 0.04, n ¼ 3; miR2 2.54 + 0.09, n ¼ 3, P , 0.005) in comparison with basal B-RAF activity ( Figure 5E ).
RCN1 expression does not alter RAS activity but inhibits C-RAF induced MEK1/2 phosphorylation
The inhibition of B-RAF by RCN1 could be due to an inhibition of RAS, which are the upstream regulators of the RAF proteins. However, overexpression of RCN1 did not alter RAS activation in NRCs transfected with increasing amounts of Ad-RCN1 as measured with an RAS activation assay ( Figure 6A ). In addition, we examined the influence of RCN1 on RAS activation after PE stimulation. However, after PE stimulation overexpression of RCN1 did not alter RAS activation in NRCs (see Supplementary material online, Figure S1 ).
C-RAF is a RAF isoform, previously demonstrated to impact on hypertrophy in cardiomyocytes. Compared with C-RAF, B-RAF has a strong basal kinase activity, allowing the possibility that RCN-mediated effects are exclusive to B-RAF. Therefore, we used a constitutively active C-RAF-BXB mutant where the amino-terminal regulatory domain of C-RAF is deleted. This renders C-RAF in a constitutively active state and was used to evaluate whether the inhibitory effect of RCN1 may extend to C-RAF-induced MEK1/2 phosphorylation. Adenoviral overexpression of RCN1 in NRCs expressing Ad-CRAF-BXB 34 
B-RAF inhibition by RCN1 is calcium dependent
Cardiac hypertrophy is accompanied by elevated cellular calcium concentrations. Therefore, we analysed whether the inhibitory effect of RCN1 may be altered by different calcium concentration in NRC culture medium. As measured by B-RAF reporter, assay inhibition of B-RAF by RCN1 in NRCs cultivated in medium with low calcium concentration (LCa 0.9 mmol/L, 0.50 + 0.01) is significantly increased compared with medium with normal calcium concentration (NCa 1.8 mmol/ L, 1.00 + 0.17, n ¼ 3, P , 0.005). In culture medium with high calcium concentration (HCa 2.8 mmol/L, 1.41 + 0.04), the ability of RCN1 to inhibit B-RAF activity is significantly decreased compared with NCa and LCa (n ¼ 3, P , 0.0001). 
Discussion
Here we show, for the first time, that B-RAF plays an important role in the regulation of cardiomyocyte hypertrophy. Additionally, we identified RCN1 as new negative modulator of B-RAF and C-RAF induced MEK1/2 phosphorylation using an unbiased genome-wide cDNA library-based reporter assay for B-RAF/MEK1 interaction. Inhibition of B-RAF, both through its pharmacological inhibitor or its negative modulator RCN1, completely abrogated cardiomyocyte hypertrophy and hypertrophic ANF-and BNP-mRNA expression induced by the hypertrophic agonist PE. Conversely, down-regulation of RCN1 leads to a hypertrophic phenotype in cardiomyocytes with increased ANF and BNP expression. Thus, RCN1 is a potent negative modulator of cardiomyocyte hypertrophy via inhibition of the pro-hypertrophic RAF/ MEK pathway. It is well established that the treatment of cultured cardiomyocytes with hypertrophic agonists such as PE results in activation of G-protein coupled receptors which mediate their effect through downstream pathways such as the RAS/RAF/MEK signalling cascade. 35 Studies using pharmacological inhibitors revealed that the activation of the hypertrophic protein 22 In our in vitro model of PE-induced hypertrophy also, B-RAF activation seems to be essential for hypertrophic response as markedly argumented by our inhibition studies with B-RAF in NRCs. C-RAF-BXB constitutively associates with B-RAF and co-expression of RAS does not appear to enhance this association. 26 This leads us to hypothesize that the activation of both B-RAF and C-RAF is necessary for the development of cardiomyocyte hypertrophy. Likewise, Galabova-Kovacs et al. concluded that activation of the MAPK signalling cascade can be initiated in vivo by at least two RAF homologues, B-RAF and C-RAF. 38 We identified RCN1 as a new negative regulator of cardiac hypertrophy. In COS cells, overexpression of RCN1 lead to a 41% reduction in unstimulated B-RAF-mediated MEK-1 association. In NRCs the overexpression of RCN1 completely impeded hypertrophic growth of cardiomyocytes and expression of ANF and BNP. In contrast, down-regulation of RCN1 leads to a hypertrophic phenotype and increased ANF-and BNP-mRNA expression in NRCs. The underlining mechanism of the anti-hypertrophic properties of RCN1 is a reduction of B-RAF-and C-RAF-induced MEK-1/2 phosphorylation. RCN1 belongs to the CREC protein family of Ca 2+ -binding proteins containing multiple EF-hand motives. However, when measured with rate dialysis technique, RCN1 failed to exhibit a high affinity Ca 2+ binding. 39 In our study, Ca 2+ binding seems to affect the function of RCN1 because the inhibitory function on B-RAF activation is altered by changes in calcium content of culture medium. Additional studies are required to decipher how local Caconcentrations and additional factors might regulate RCN1 activity. A role for RCN1 in cardiac physiology was not described previously, and knowledge on RCN1 is very limited. Since dysregulation of RCN proteins has been reported in various diseases, such as cancer, cardiovascular, and neuromuscular diseases 40 -42 and the high degree of amino acid conservation among homologues from human, mouse, and rat species, there are some indirect evidence that RCN1 proteins may serve important conserved cellular functions. Moreover, RCN1 seems to play an important role because homozygous deletion of the Rcn1 gene is incompatible with the life of mice. 43 Mouse RCN1 was originally cloned by Ozawa and Muramatsu in 1993. 44 The 331 amino acid precursor comprises a signal sequence, six EF-hand motives and an endoplasmic reticulum (ER) retention signal HDEL that originally was reported to retain the protein strictly in the ER. However, recent studies showed that RCN1 is also localized at the cell surface of bone endothelial cells and prostate cancer cells. The mechanism for the expression in the plasma membrane is unknown, but could be explained by a novel proline ER export signal, which is also conserved in members of the CREC protein family, like RCN1, CAB45, and calumenin. 46 The fact that RCN1 modulates cardiac hypertrophy does not explain how exactly it impedes cardiomyocyte growth via RAF proteins. A multitude of scaffolding and adaptor proteins concert RAFmediated activation towards MEK, allowing for the possibility that RCN1 might require a particular complex. Nevertheless, our overexpression and down-regulation studies using the mammalian two-hybrid interaction screen and data in NRCs suggest that RCN1 exerts its anti-hypertrophic properties through modulation of the MEK/RAF signalling cascade downstream of RAS. RCN1 expression is up-regulated under conditions of afterloadinduced cardiac hypertrophy, in our mouse model. This distinct regulation suggests a possible involvement of the protein in cardiac hypertrophy progression and cell growth. RCN1 is up-regulated after the induction of hypertrophy in our animal model; therefore, our data suggest that RCN1 limits hypertrophic gene expression in states of RAS-induced hypertrophic growth. A counter-regulatory role of RCN1 on stress signalling is in line with earlier observations that RCN1 is regulated by additional factors playing an important role in the development of cardiac disease. Cooper et al. showed that the surface expression of RCN1 is increased in the presence of TNF-a, a pro-inflammatory cytokine that is often overexpressed in heart failure. 45 Additionally, overexpression of C-reactive protein which has been associated with increased cardiovascular risk leads to down-regulation of RCN1 and an increased activation of the MEK/ERK signalling pathway 47, 48 similar to our down-regulation studies in NRCs. In summary, we identified B-RAF as an important MEK kinase in cardiomyocyte hypertrophy. Additionally, we identified RCN1 as novel regulator of cardiomyocyte hypertrophy impeding B-RAF/MEK interaction. Whereas RCN1 inhibited agonist induced hypertrophy, its depletion caused a hypertrophic phenotype. The underlining mechanism of the anti-hypertrophic properties of RCN1 is a reduction of B-RAF activity and inhibition of B-RAF, and C-RAF induced MEK1/2 phosphorylation.
Supplementary material
Supplementary material is available at Cardiovascular Research online. Western blot analysis after RAS activation assay revealed no differences in RAS activity after overexpression of RCN1 (n ¼ 3). (B) An overexpressed constitutive active mutant of C-RAF (C-RAF-BXB) in NRCs showed reduced MEK1/2 phosphorylation after overexpression of RCN1 in a dosedependent manner (n ¼ 3). (C) B-RAF reporter assay was carried out in NRCs cultivated in medium with different calcium concentrations. B-RAF activation was significantly elevated after incubation in medium with rising calcium concentrations (n ¼ 3) (*P , 0.05; **P , 0.005; ***P , 0.0001).
